Skip to main content
SpringerLink
Log in

Patients with asthma should use intermediate-acting inhaled β2-agonists only on an as-needed basis

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Cockcroft DW. As-needed inhaled β2-adrenoceptor agonists in moderate-to-severe asthma. Treat Respir Med 2005; 4(3): 169–74

    Article  PubMed  Google Scholar 

  2. National Institutes of Health. Global Initiative for Asthma: pocket guide for asthma management and prevention. Publication No. 95-3659B. Bethesda (MD): National Institute of Health, National Heart Lung and Blood Institute, 1998

  3. Boulet LP, Becker A, Berube D, et al. Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group. CMAJ 1999; 161: Sl–61

    Google Scholar 

  4. Walters EH, Walters J. Inhaled short-acting beta 2-agonist use in asthma: regular versus as needed treatment. Cochrane Database Syst Rev 2003; (2): CD001285

    PubMed  Google Scholar 

  5. Suissa S, Ernst P, Boivin JF, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med 1994; 149: 604–10

    PubMed  CAS  Google Scholar 

  6. Abramson MJ, Bailey MJ, Couper FJ, et al. Are asthma medications and management related to deaths from asthma? Am J Respir Crit Care Med 2001; 163: 12–8

    PubMed  CAS  Google Scholar 

  7. Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391–6

    Article  PubMed  CAS  Google Scholar 

  8. Taylor DR, Sears MR, Herbison GP, et al. Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. Thorax 1993; 48: 134–8

    Article  PubMed  CAS  Google Scholar 

  9. Cockcroft DW, McParland CP, Britto SA, et al. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 1993; 342: 833–7

    Article  PubMed  CAS  Google Scholar 

  10. Cockcroft DW, O’Byrne PM, Swystun VA, et al. Regular use of inhaled albuterol and the allergen-induced late asthmatic response. J Allergy Clin Immunol 1995; 96: 44–9

    Article  PubMed  CAS  Google Scholar 

  11. Cockcroft DW, Swystun VA, Bhagat R. Interaction of inhaled beta 2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Am J Respir Crit Care Med 1995; 152: 1485–9

    PubMed  CAS  Google Scholar 

  12. Bhagat R, Swystun VA, Cockcroft DW. Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response. J Allergy Clin Immunol 1996; 97: 47–52

    Article  PubMed  CAS  Google Scholar 

  13. Gauvreau GM, Jordana M, Watson RM, et al. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am J Respir Crit Care Med 1997; 156: 1738–45

    PubMed  CAS  Google Scholar 

  14. Swystun VA, Gordon JR, Davis EB, et al. Mast cell tryptase release and asthmatic responses to allergen increase with regular use of salbutamol. J Allergy Clin Immunol 2000; 106: 57–64

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patients with asthma should use intermediate-acting inhaled β2-agonists only on an as-needed basis. Drugs Ther. Perspect 22, 12–13 (2006). https://doi.org/10.2165/00042310-200622010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200622010-00004

Search

Navigation